心血管

订阅

MedSci主页 / 所有栏目 / 心血管

Eur Heart J：治疗NSTE-ACS 替格瑞洛优于氯吡格雷

2014-04-21 高晓方 译 医学论坛网

NSTE-ACS替格瑞洛氯吡格雷
关注

欧美一项研究表明，在非ST段抬高型急性冠脉综合征(NSTE-ACS)患者中，替格瑞洛在减少缺血性事件和总体死亡率方面均优于氯吡格雷，并且独立于早期是否实施血运重建。论文于4月11日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项研究从PLATO试验中共纳入11080例NSET-ACS患者，并在上述患者以及随机化10天内接受和未接受血运重建的亚组患者中对比评估了替格瑞洛和氯吡格雷的

欧美一项研究表明，在非ST段抬高型急性冠脉综合征(NSTE-ACS)患者中，替格瑞洛在减少缺血性事件和总体死亡率方面均优于氯吡格雷，并且独立于早期是否实施血运重建。论文于4月11日在线发表于《欧洲心脏杂志》(Eur Heart J)。

此项研究从PLATO试验中共纳入11080例NSET-ACS患者，并在上述患者以及随机化10天内接受和未接受血运重建的亚组患者中对比评估了替格瑞洛和氯吡格雷的有效性和安全性。主要终点为心血管死亡、心梗或卒中。

结果显示，在最初10天内，接受血管造影、经皮冠状动脉介入治疗(PCI)和冠状动脉旁路移植术(CABG)的患者分别占74%、46%和5%。替格瑞洛和氯吡格雷分别使主要终点减少10.0%和12.3%(HR 0.83)。两组患者的大出血发生率相似，但替格瑞洛与非CABG大出血增多具有相关性(HR 1.28)。无论在最初10天是否实施血运重建，替格瑞洛均可使主要转归和全因死亡出现一致性减少，并且未显著增加总体大出血发生率。

原始出处：


Lindholm D1, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK.Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.Eur Heart J. 2014 Apr 11. [Epub ahead of print]


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1977490, encodeId=db5b19e74901d, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Jan 27 01:28:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947575, encodeId=3410194e57514, content=<a href='/topic/show?id=a0291309883' target=_blank style='color:#2F92EE;'>#NSTE-ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13098, encryptionId=a0291309883, topicName=NSTE-ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Jun 14 18:28:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279052, encodeId=6ddc12e9052fa, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355851, encodeId=287e13558514f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562228, encodeId=3f6715622281a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2015-01-27 drj2003

    #NST#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1977490, encodeId=db5b19e74901d, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Jan 27 01:28:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947575, encodeId=3410194e57514, content=<a href='/topic/show?id=a0291309883' target=_blank style='color:#2F92EE;'>#NSTE-ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13098, encryptionId=a0291309883, topicName=NSTE-ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Jun 14 18:28:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279052, encodeId=6ddc12e9052fa, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355851, encodeId=287e13558514f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562228, encodeId=3f6715622281a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2014-06-14 12498bd5m16暂无昵称

    #NSTE-ACS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1977490, encodeId=db5b19e74901d, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Jan 27 01:28:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947575, encodeId=3410194e57514, content=<a href='/topic/show?id=a0291309883' target=_blank style='color:#2F92EE;'>#NSTE-ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13098, encryptionId=a0291309883, topicName=NSTE-ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Jun 14 18:28:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279052, encodeId=6ddc12e9052fa, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355851, encodeId=287e13558514f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562228, encodeId=3f6715622281a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2014-04-23 yaanren

    #ACS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1977490, encodeId=db5b19e74901d, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Jan 27 01:28:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947575, encodeId=3410194e57514, content=<a href='/topic/show?id=a0291309883' target=_blank style='color:#2F92EE;'>#NSTE-ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13098, encryptionId=a0291309883, topicName=NSTE-ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Jun 14 18:28:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279052, encodeId=6ddc12e9052fa, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355851, encodeId=287e13558514f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562228, encodeId=3f6715622281a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2014-04-23 zhaojie88

    #ART#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1977490, encodeId=db5b19e74901d, content=<a href='/topic/show?id=d9e5130962f' target=_blank style='color:#2F92EE;'>#NST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13096, encryptionId=d9e5130962f, topicName=NST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Tue Jan 27 01:28:00 CST 2015, time=2015-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1947575, encodeId=3410194e57514, content=<a href='/topic/show?id=a0291309883' target=_blank style='color:#2F92EE;'>#NSTE-ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13098, encryptionId=a0291309883, topicName=NSTE-ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Sat Jun 14 18:28:00 CST 2014, time=2014-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1279052, encodeId=6ddc12e9052fa, content=<a href='/topic/show?id=316d1882bc' target=_blank style='color:#2F92EE;'>#ACS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1882, encryptionId=316d1882bc, topicName=ACS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355851, encodeId=287e13558514f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562228, encodeId=3f6715622281a, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Wed Apr 23 00:28:00 CST 2014, time=2014-04-23, status=1, ipAttribution=)]
    2014-04-23 爆笑小医

    #HEART#

    0

相关资讯

NSTE-ACS诊疗措施推陈出新

　此次新颁布的四大指南都历经了一年半以上的编写及3遍以上的审阅。除查阅大量文献，反映最新研究进展，指南制订者们还通过设计一系列简洁直观的图表或提供更具操作性的建议，提升指南的实用价值，并缩小与临床实践之间的差距。 　　一再更新，在变化中不断进步 　　诊断与危险分层更新点 　　证据级别提升：对疑似非ST段抬高急性冠脉综合征（NSTE-ACS）患者，应据病史、症状、体格检查、心电图和生物标志物结

JAMA：行PCI手术NSTE-ACS患者不建议使用奥米沙班

研究要点： 研究人员开展TAO研究，旨在比较对于行介入治疗的NSTE-ACS患者，单用奥米沙班与普通肝素联用埃替非巴肽（UFH-plus-eptifibatide）的疗效与安全性。 研究结果显示，奥米沙班与普通肝素联用埃替非巴肽治疗相比，不能降低缺血性事件发生风险且可增加出血风险。研究结果不支持对早期行PCI手术的NSTE-ACS患者使用奥米沙班。 研究结果发表在JAMA杂志9月

AHJ：TAO研究将评估奥米沙班有效性和安全性

　　美国学者正在实施的TAO研究将以非ST段抬高急性冠脉综合征（NSTE-ACS）患者为受试者，并对奥米沙班的临床有效性和安全性加以评估。论文于2012年11月8日在线发表于《美国心脏杂志》（AHJ）。 　　奥米沙班为高选择性Xa因子直接抑制剂。一项在ACS患者中实施的临床Ⅱ期试验显示，与普通肝素（UFH）和依替巴肽相比，中等剂量奥米沙班可显著减少由死亡或心梗组成的复合终点，并且出血发生率相似。